INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

STROSUTRO BIOPHARMA, INC.

CIK 0001382101

EDGAR filingsOpen in network
Disclosed transactions27
Buys / sells0 / 0
Max Insider Score21
Connections6with evidence

STRO · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
13
GP
Gerber Hans-PeterCHIEF SCIENTIFIC OFFICER
STROSUTRO BIOPHARMA, INC.
Tax withholding
F$21K
1,345 sh
Sep 18, 2026Sep 22, 2026
traded Sep 18, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Gerber Hans-PeterCHIEF SCIENTIFIC OFFICER · Dec 29, 2025
  • ← Insider ofevidence
    Chow Gregory K.CFO · Dec 29, 2025
  • ← Insider ofevidence
    Pauling DavidChief Admin. Ofcr. & GC · Dec 29, 2025
  • ← Insider ofevidence
17
GP
Gerber Hans-PeterCHIEF SCIENTIFIC OFFICER
STROSUTRO BIOPHARMA, INC.
Option exercise
M
—
3,750 sh
Sep 18, 2026
Sep 22, 2026
traded Sep 18, 2026
+4d
SEC FORM 4

Evidence

9
GP
Gerber Hans-PeterCHIEF SCIENTIFIC OFFICER
STROSUTRO BIOPHARMA, INC.
Option exercise
M—
3,750 sh
Sep 18, 2026Sep 22, 2026
traded Sep 18, 2026
+4dSEC FORM 4

Evidence

9
HH
Hunter HeidiDirector
STROSUTRO BIOPHARMA, INC.
Grant or award
A—
10.0K sh
Jun 5, 2026Jun 9, 2026
traded Jun 5, 2026
+4dSEC FORM 4

Evidence

9
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Tax withholding
F$5,903
277 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC FORM 4

Evidence

9
CJ
Chung JaneDirector, Chief Executive Officer
STROSUTRO BIOPHARMA, INC.
Option exercise
M—
788 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC FORM 4

Evidence

9
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Option exercise
M—
675 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC FORM 4

Evidence

9
CJ
Chung JaneDirector, Chief Executive Officer
STROSUTRO BIOPHARMA, INC.
Tax withholding
F$6,009
282 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC FORM 4

Evidence

9
CJ
Chung JaneDirector, Chief Executive Officer
STROSUTRO BIOPHARMA, INC.
Option exercise
M—
788 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC FORM 4

Evidence

13
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Option exercise
M—
675 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC FORM 4

Evidence

21
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Option exercise
M—
842 sh
Mar 1, 2026Mar 3, 2026
traded Mar 1, 2026
+2dSEC FORM 4

Evidence

13
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Tax withholding
F$20K
970 sh
Mar 2, 2026Mar 3, 2026
traded Mar 2, 2026
+1dSEC FORM 4

Evidence

17
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Option exercise
M—
2,356 sh
Mar 2, 2026Mar 3, 2026
traded Mar 2, 2026
+1dSEC FORM 4

Evidence

9
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Grant or award
A—
4,200 sh
Mar 2, 2026Mar 3, 2026
traded Mar 2, 2026
+1dSEC FORM 4

Evidence

9
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Grant or award
A—
33.6K sh
Mar 2, 2026Mar 3, 2026
traded Mar 2, 2026
+1dSEC FORM 4

Evidence

13
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Option exercise
M—
500 sh
Mar 1, 2026Mar 3, 2026
traded Mar 1, 2026
+2dSEC FORM 4

Evidence

13
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Option exercise
M—
842 sh
Mar 1, 2026Mar 3, 2026
traded Mar 1, 2026
+2dSEC FORM 4

Evidence

13
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Tax withholding
F$11K
551 sh
Mar 1, 2026Mar 3, 2026
traded Mar 1, 2026
+2dSEC FORM 4

Evidence

17
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Option exercise
M—
2,356 sh
Mar 2, 2026Mar 3, 2026
traded Mar 2, 2026
+1dSEC FORM 4

Evidence

9
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Option exercise
M—
500 sh
Mar 1, 2026Mar 3, 2026
traded Mar 1, 2026
+2dSEC FORM 4

Evidence

15
GP
Gerber Hans-PeterCHIEF SCIENTIFIC OFFICER
STROSUTRO BIOPHARMA, INC.
Grant or award
A—
7,925 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC FORM 4

Evidence

15
HH
Hunter HeidiDirector
STROSUTRO BIOPHARMA, INC.
Grant or award
A—
1,500 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC FORM 4

Evidence

15
CK
Chow Gregory K.CFO
STROSUTRO BIOPHARMA, INC.
Grant or award
A—
8,200 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC FORM 4

Evidence

15
PD
Pauling DavidChief Admin. Ofcr. & GC
STROSUTRO BIOPHARMA, INC.
Grant or award
A—
7,200 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC FORM 4

Evidence

21
CJ
Chung JaneDirector, Chief Executive Officer
STROSUTRO BIOPHARMA, INC.
Option exercise
M—
2,500 sh
Dec 12, 2025Dec 16, 2025
traded Dec 12, 2025
+4dSEC FORM 4

Evidence

13
CJ
Chung JaneDirector, Chief Executive Officer
STROSUTRO BIOPHARMA, INC.
Tax withholding
F$7,165
894 sh
Dec 12, 2025Dec 16, 2025
traded Dec 12, 2025
+4dSEC FORM 4

Evidence

17
CJ
Chung JaneDirector, Chief Executive Officer
STROSUTRO BIOPHARMA, INC.
Option exercise
M—
2,500 sh
Dec 12, 2025Dec 16, 2025
traded Dec 12, 2025
+4dSEC FORM 4

Evidence

Hunter Heidi
Director · Dec 29, 2025
  • ← Insider ofevidence
    Chung JaneDirector, Chief Executive Officer · Dec 16, 2025